Low-Dose CDK4/6 Inhibitors Induce Presentation of Pathway Specific MHC Ligands as Potential Targets for Cancer Immunotherapy

Researchers investigated the effects of CDK4/6i, abemaciclib and palbociclib, on the immunopeptidome at nontoxic levels in breast cancer cell lines using biochemical identification of HLA ligands followed by network analyses.